Phase I study of flavopiridol in combination with paclitaxel and carboplatin in patients with non-small-cell lung cancer

Clinical Lung Cancer

Volumn 9, Issue 3, 2008, Pages 160-165

  George, Saby ^a   Kasimis, Basil S ^b   Cogswell, Janet ^b   Schwarzenberger, Paul ^c   Shapiro, Geoffrey I ^d   Fidias, Panos ^e   Bukowski, Ronald M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Southern Cancer Center   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Asthenia; Cardiac toxicity; CDK inhibitors; Cyclin D1

Indexed keywords

CARBOPLATIN; FLAVOPIRIDOL; PACLITAXEL;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; ATELECTASIS; BRAIN HEMORRHAGE; CANCER STAGING; CARCINOMA; CARDIOPULMONARY ARREST; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; FEMALE; HEADACHE; HEART INFARCTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INSOMNIA; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PAIN; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; SIDE EFFECT; SINUS TACHYCARDIA; SORE THROAT; SUPRAVENTRICULAR PREMATURE BEAT; SWEATING; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNITED STATES; VOMITING;

EID: 45849087334     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2008.n.024     Document Type: Article

References (32)

1. Drees M, Dengler WA, Roth T, et al. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res 1997; 3:273-9.
2. Carlson BA, Dubay MM, Sausville EA, et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56:2973-8.
3. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001; 38:139-70.
4. Kaur G, Stetler-Stevenson M, Sebers S, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst 1992; 84:1736-40.
5. Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs 2000; 9:2903-11.
6. Chao SH, Fujinaga K, Marion JE, et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000; 275:28345-8.
7. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001; 276:31793-9.
8. de Azevedo WF Jr, Canduri F, da Silveira NJ. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002; 293:566-71.
9. Carlson B, Lahusen T, Singh S, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999; 59:4634-41.
10. Chen R, Keating MJ, Gandhi V, et al. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 2005; 106:2513-9.
11. Wittmann S, Bali P, Donapaty S, et al. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 2003; 63:93-9.
12. Bible KC, Kaufmann SH. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997; 57:3375-80.
13. Galmarini CM, Falerte N, Tabone E, et al. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. Br J Cancer 2001; 85:902-8.
14. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999; 5:1876-83.
15. Pathan N, Aime-Sempe C, Kitada S, et al. Microtubule-targeting drugs induce bcl-2 phosphorylation and association with Pin1. Neoplasia 2001; 3:550-9.
16. Shapiro GI, Koestner DA, Matranga CB, et al. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1999; 5:2925-38.
17. Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001; 7:1590-9.
18. Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid rumors. J Clin Oncol 2002; 20:2157-70.
19. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 1996; 14:2054-60.
20. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13:1860-70.
21. Chatelut E, Pivot X, Otto J, et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 2000; 36:264-9.
22. Paraplatin® (carboplatin aqueous solution) Injection. Full prescribing information. Bristol-Myers Squibb; 2005.
23. Taxol® (paclitaxel) injection. Package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2007.
24. Stadler WM, Vogelzang NJ, Amato R, et al. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago phase II consortium study. J Clin Oncol 2000; 18:371-5.
25. Belani CP. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments. Semin Oncol 1999; 26(suppl 10):15-8.
26. Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer parients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18:623-31.
27. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplarin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210-8.
28. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12:360-7.
29. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-30.
30. Schiller J, Harrington D, Sandler A, et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell cancer (NSCLC). Proc Am Soc Clin CW/2000; 19:1a (Abstract 2).
31. Bible KC, Lensing JL, Nelson SA, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005; 11:5935-41.
32. Byrd JC, Lin TS, Dalton JT, et al. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007; 109:399-404.